Hepatitis C, stigma and cure

World Journal of Gastroenterology

Volumn 19, Issue 40, 2013, Pages 6703-6709

  Marinho, Rui Tato ^a   Barreira, David Pires ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Chronic; Depression; Hepatic cirrhosis; Hepatitis C; Hepatocellular carcinoma; Interferon alpha; Ribavirin; Social stigma; Therapy

Indexed keywords

ABT 450; ASUNAPREVIR; BOCEPREVIR; DELEOBUVIR; FALDAPREVIR; INTERFERON; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; DEPRESSION; ECHOGRAPHY; EDITORIAL; FATIGUE; GENOTYPE; HEPATITIS C; HOSPITALIZATION; HUMAN; INFECTION RISK; INSOMNIA; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOSS OF APPETITE; MENTAL HEALTH; QUALITY OF LIFE; RNA VIRUS INFECTION; SIDE EFFECT; STIGMA; SUICIDAL IDEATION; SURVIVAL; TRANSITORY ELASTOGRAPHY; VIRUS LOAD;

CHRONIC; DEPRESSION; HEPATIC CIRRHOSIS; HEPATITIS C; HEPATOCELLULAR CARCINOMA; INTERFERON-ALPHA; RIBAVIRIN; SOCIAL STIGMA; THERAPY;

ACCESS TO INFORMATION; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MENTAL HEALTH; PREJUDICE; PUBLIC OPINION; QUALITY OF LIFE; REMISSION INDUCTION; STEREOTYPING; TREATMENT OUTCOME;

EID: 84886993244     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i40.6703     Document Type: Editorial

References (65)

1. Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011; 33: 559-565 [PMID: 21198704 DOI: 10.1111/j.1365-2036.2010.04549.x]
2. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310 [PMID: 16729298 DOI: 10.1002/hep.21176]
3. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]
4. Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Solà R. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823-830 [PMID: 15094231 DOI: 10.1016/j.jhep.2004.01.005]
5. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-749 [PMID: 15082595]
6. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259 [PMID: 11156649]
7. Talwalkar JA. Determining the extent of quality health care for hospitalized patients with cirrhosis. Hepatology 2005; 42: 492-494 [PMID: 15942950 DOI: 10.1002/hep.20753]
8. Roche B, Samuel D. Hepatitis C virus treatment pre-and post-liver transplantation. Liver Int 2012; 32 Suppl 1: 120-128 [PMID: 22212582 DOI: 10.1111/j.1478-3231.2011.02714.x]
9. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19: 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793]
10. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562]
11. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364 [PMID: 2496467]
12. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-1578 [PMID: 3097544 DOI: 10.1056/ nejm198612183152503]
13. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
15. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
16. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303 [PMID: 20375406 DOI: 10.1056/NEJMoa0908014]
17. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-662 [PMID: 23183526 DOI: 10.1016/j.jhep.2012.09.037]
18. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. A phase 2a trial of 12-week interferonfree therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; 59: 18-23 [PMID: 23439262 DOI: 10.1016/j.jhep.2013.02.009]
19. Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18: 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514]
20. Miller ER, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis c--a systematic narrative review of the literature. BMC Public Health 2012; 12: 672 [PMID: 22900973 DOI: 10.1186/1471-2458-12-672]
21. Braitstein P, Montessori V, Chan K, Montaner JS, Schechter MT, O'Shaughnessy MV, Hogg RS. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005; 17: 505-515 [PMID: 16036236 DOI: 10.1080/09540120412 331291733]
22. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-816 [PMID: 17326207 DOI: 10.1002/ hep.21565]
23. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157: 867-876 [PMID: 10831463]
24. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-1390 [PMID: 22878466 DOI: 10.1016/j.jhep.2012.07.037]
25. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 785-789 [PMID: 9625128 DOI: 10.1111/j.1572-0241.1998.225_a.x]
26. Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, Ewing SL, Ho SB. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002; 97: 1813-1820 [PMID: 12135041 DOI: 10.1111/ j.1572-0241.2002.05800.x]
27. Almasio PL, Cottone C, D'Angelo F. Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment. Dig Liver Dis 2007; 39 Suppl 1: S88-S95 [PMID: 17936232]
28. Alvarez F. Therapy for chronic viral hepatitis. Clin Invest Med 1996; 19: 381-388 [PMID: 8889278]
29. Angelino AF, Treisman GJ. Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. Int Rev Psychiatry 2005; 17: 471-476 [PMID: 16401545 DOI: 10.1080/02646830500381567]
30. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 2005; 7: 391-395 [PMID: 16216160]
31. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27: 431-438 [PMID: 16271658 DOI: 10.1016/j.genhosppsych.2005.06.006]
32. Falasca K, Mancino P, Ucciferri C, Dalessandro M, Manzoli L, Pizzigallo E, Conti CM, Vecchiet J. Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. Clin Invest Med 2009; 32: E212-E218 [PMID: 19480737]
33. von Ammon Cavanaugh S. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics 1995; 36: 48-59 [PMID: 7871134]
34. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, Robbins SC, Younossi ZM. Depression, anemia and healthrelated quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491-498 [PMID: 16427157 DOI: 10.1016/j.jhep.2005.11.046]
35. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand 2004; 19: 35-39 [PMID: 15521414]
36. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026]
37. Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2007; 18: 364-373 [PMID: 17854724 DOI: 10.1016/ j.drugpo.2007.02.004]
38. Schäfer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000; 95: 1101-1104 [PMID: 10962774]
39. Bogart LM, Cowgill BO, Kennedy D, Ryan G, Murphy DA, Elijah J, Schuster MA. HIV-related stigma among people with HIV and their families: a qualitative analysis. AIDS Behav 2008; 12: 244-254 [PMID: 17458691 DOI: 10.1007/s10461-007-9231-x]
40. Anti-Discrimination Board of New South Wales, 2001. Report of the inquiry into hepatitis C related discrimination. Available from: URL: http://www.hep.org.au/documents/ 2001CChange-3MB.pdf
41. Butt G. Stigma in the context of hepatitis C: concept analysis. J Adv Nurs 2008; 62: 712-724 [PMID: 18503656 DOI: 10.1111/ j.1365-2648.2008.04641.x]
42. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003; 18: 835-844 [PMID: 14521647]
43. Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A, Pirisi M, Smirne C, Colletta C, Traverso A, Mazzucco D, Ciccone G, Simondi D, Rizzetto M, Saracco G. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. Eur J Gastroenterol Hepatol 2013; Epub ahead of print [PMID: 23719564 DOI: 10.1097/MEG.0b013e328362dc99]
44. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferonalpha therapy. Ann Intern Med 1997; 127: 875-881 [PMID: 9382365]
45. García-Bengoechea M, Basaras M, Barrio J, Arrese E, Montalvo II, Arenas JI, Cisterna R. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy. Am J Gastroenterol 1999; 94: 1902-1905 [PMID: 10406257 DOI: 10.1111/j.1572-0241.1999.01227.x]
46. Marinho RT, Pinto RM, Santos ML, de Moura MC. Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. Liver Int 2004; 24: 413-418 [PMID: 15482336 DOI: 10.1111/j.1478-3231.2004.0947.x]
47. D'Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V, Bedossa P, Colombo M. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013; 59: 251-256 [PMID: 23528378 DOI: 10.1016/j.jhep.2013.03.013]
48. Longo S, Cotella G, Carletta F, Catacchio M, Antonaci S. Perihepatic lymphadenopathy and the response to therapy in chronic hepatitis C patients. J Ultrasound 2010; 13: 164-167 [PMID: 23396905 DOI: 10.1016/j.jus.2010.10.013]
49. Muller P, Renou C, Harafa A, Jouve E, Kaplanski G, Ville E, Bertrand JJ, Masson C, Benderitter T, Halfon P. Lymph node enlargement within the hepatoduodenal ligament in patients with chronic hepatitis C reflects the immunological cellular response of the host. J Hepatol 2003; 39: 807-813 [PMID: 14568265]
50. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313 [PMID: 11984517]
51. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-2076 [PMID: 20196120 DOI: 10.1002/hep.23528]
52. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the devel-opment of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337 [PMID: 23460056 DOI: 10.7326/0003-4819-158-5-201303050-00005]
53. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
54. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-1762 [PMID: 22821361 DOI: 10.1002/hep.25976]
55. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 2012; 57: 946-952 [PMID: 22760009 DOI: 10.1016/j.jhep.2012.06.030]
56. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36: S99-105 [PMID: 12407582 DOI: 10.1053/ jhep.2002.36797]
57. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 109-113 [PMID: 23437438]
58. Ryan Caballes F, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 2012; 32: 880-893 [PMID: 22510500 DOI: 10.1111/ j.1478-3231.2012.02794.x]
59. Koskinas J, Kilidireas C, Karandreas N, Kountouras D, Savvas S, Hadziyannis E, Archimandritis AJ. Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study. Liver Int 2007; 27: 414-420 [PMID: 17355465 DOI: 10.1111/ j.1478-3231.2006.01436.x]
60. Ito A, Kazama T, Ito K, Ito M. Purpura with cold urticaria in a patient with hepatitis C virus infection-associated mixed cryoglobulinemia type III: successful treatment with interferon-beta. J Dermatol 2003; 30: 321-325 [PMID: 12707469]
61. Namba T, Shiba R, Yamamoto T, Hirai Y, Moriwaki T, Matsuda J, Kadoya H, Takeji M, Yamada Y, Yoshihara H, Yamauchi A. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol 2010; 14: 372-376 [PMID: 20467773 DOI: 10.1007/ s10157-010-0282-3]
62. Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94 [PMID: 12110736 DOI: 10.1056/NEJMoa013376]
63. Nunes J, Tato Marinho R, Raposo J, Velosa J. [Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes]. Acta Med Port 2010; 23: 941-944 [PMID: 21144339]
64. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-290 [PMID: 22351713 DOI: 10.1059/0003-4 819-156-4-201202210-00005]
65. Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, Murthy K, Marincola FM, Alter HJ. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 2013; 57: 483-491 [PMID: 22729600 DOI: 10.1002/hep.25921]